A DEEP AND DIVERSE PIPELINE
Committed to bringing quality of life to people by translating science into highly-innovative therapeutics
The impossible is simply what hasn’t been achieved yet. Perpetuum’s research and development program is focused on what’s next. We aspire to be a dynamic R&D organization by focusing on the best science for those therapies that can deliver true innovation for patients and payers.
The studies into the safety and efficacy of investigational products provide data to support applications to regulators for approval. The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not yet been established. These uses have therefore not been approved by the U.S. Food and Drug Administration or other regulatory authorities.
The content of our development pipeline will change over time as new projects progress from research to development and from development to the market.
SPEEDPHARMING PLATFORM
VACCINES - HUMAN/VETERINARY
COVID-19 VLP
(PCS-PH08)
A virus-like particle (VLP) based vaccine for the COVID-19 disease caused by the SARS-CoV-2 strain of coronavirus. VLP based vaccines are known to interact with immune cells differently than soluble antigens and can trigger both humoral and cellular responses.
Co-formulated in our dendritic nano-adjuvant emulsions.
Partners:
Pre-clinical
Classical swine fever
(PCS-VM02)
DIVA-capable subunit vaccine for classical swine fever (CSF); a contagious, often fatal, disease affecting both feral and domesticated pigs. Outbreaks do not only adversely impact animal health and food security but have also have severe socio-economic impacts on both the pig industry worldwide and small scale pig farming.
Studies have shown that after single-dose vaccination, the adjuvanted, plant-made CSF E2 subunit vaccine provides complete protection in challenged pigs and is accompanied by strong virus neutralization antibody responses.
Co-formulated in our dendritic nano-adjuvant emulsions
Partners:
Proof of principle
Pre-clinical
Clinical development
DIABETES
Diabetic foot ulcer
(PCS-PH08)
GPI anchored TXNIP/TIMP1 recombinant chimeric for the treatment of diabetic foot ulcer (DFU); one of the most significant and devastating complications of diabetes, and is defined as a foot affected by ulceration that is associated with neuropathy and/or peripheral arterial disease of the lower limb in a patient with diabetes.
Formulated in our NucleoSacran biodegradable gel formulation
Pre-clinical
DERMATOLOGY/COSMETIC
Rosacea
(PCS-MD06)
Bradykinin inhibitor for the treatment of rosacea; a chronic disorder characterized by hypersensitivity of the facial vasculature, presenting with intense flushing eventually leading to chronic erythema and telangiectasia. PCS-MD06 antagonizes the vasodilatory actions of bradykinin at the B2 bradykinin receptor (BDKRB2).
Formulated in our NucleoSacran biodegradable gel formulation
Pre-clinical
Radiodermatitis
(PCS-MD05)
Recombinant Verectin is an inhibitor of cyclooxygenase-2 (COX-2) for the treatment of radiodermatitis; a severe acute and late pathophysiological consequence of radiotherapy in cancer patients. PCS-MD05 is a promising antioxidant COX-2 inhibitor-based radioprotectant because of intercepting radiation-induced oxidative stress and inflammation in normal tissue, especially the vascular system.
Formulated in our NucleoSacran biodegradable gel formulation.
Pre-clinical
Phase-1
PLANT CELL EXTRACTION PLATFORM
ANTI-POLLUTION / COSMETIC
PolluProtec
(PCS-CO01)
PolluProtec is a blend of two cosmetic active ingredients produced by our in-vitro plant cell extraction platform. Cell extracts from Arabian Jasmine and Edelweiss from the Swiss Alps offer a unique biological protection for the skin.
PolluProtec is a reinforced assimilation of active molecules from both plant cell extracts that decrease damages made on skin cell DNA and protects from environmental agressions.
Formulation: Glycerin (vegetable – 62%), Water (8%), Leontopodium Alpinum Callus Culture Extract (15%), Jasminum sambac leaf cell extract (15%)
Discovery
Safety
In-vitro / In-vivo
Commercialization
ANTI-AGING / COSMETIC
Aevum
(PCS-CO03)
Aevum is an extract of the cells produced by fusion between protoplasts of stem tissue from Gynostemma pentaphyllum and cotyledon tissue from Luffa cylindrica.
Aevum is a reinforced assimilation of active molecules from both plants which can help to relaunch collagen, GAG synthesis, and increase epidermal cell renewal, resulting in enhanced suppleness of the skin and a reduction of fine lines and wrinkles.
Formulation: Glycerin (vegetable – 62%), Water (8%), Gynostemma Pentaphyllum/Luffa Cylindrica Hybrid Cell Extract (30%)
Discovery
Safety
In-vitro / In-vivo
Commercialization
DISSOLVING MICRONEEDLE PLATFORM
SKIN IMPROVEMENT / COSMETIC
Nucleo Mg
(PCS-CO04)
Nucleo Mg is our newest dissolving microcarrier that delivers a fixed dose of the magnesium salt of highly polymerized Deoxyribonucleic acid (Magnesium DNA) and bioabsorbable magnesium.
It offers a plethora of beneficial effects of both Deoxyribonucleic acid and magnesium combined. Nucleo Mg offers molecular hydrogen generation (antibacterial, and antioxidant effects) due to the ionization reacton of magnesium with the water content of the skin and stimulates angiogenesis, improving skin texture.